ARTYKUŁ PRZEGLĄDOWY
Aktywność układu JAK/STAT oraz NF-kB u chorych na spondyloartropatie osiowe
Jerzy Świerkot 1 , Renata Sokolik 1 , Anna Czarny 2 , Ewa Zaczyńska 2 , Beata Nowak 3 , Arkadiusz Chlebicki 4 , Lucyna Korman 1 , Marta Madej 1 , Patryk Wojtala 4 , Łukasz Lubiński 4 , Piotr Wiland 11. Department of Rheumatology and Internal Medicine, Wroclaw Medical University
2. L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
3. Department of Pharmacology, Wroclaw Medical University, Wroclaw
4. Department of Rheumatology and Internal Medicine, Wroclaw University Hospital
Opublikowany: 2015-12-02
DOI: 10.5604/17322693.1184460
GICID: 01.3001.0009.6600
Dostępne wersje językowe: pl en
Wydanie: Postepy Hig Med Dosw 2015; 69 : 1291-1298
Abstrakt
Przypisy
- 1. Amor B., Santos R.S., Nahal R., Listrat V., Dougados M.: Predictivefactors for the longterm outcome of spondyloarthropathies. J.Rheumatol., 1994; 21: 1883-1887
Google Scholar - 2. Calin A., Garrett S., Whitelock H., Kennedy L.G., O’Hea J., MallorieP., Jenkinson T.: A new approach to defining functional abilityin ankylosing spondylitis: the development of the Bath AnkylosingSpondylitis Functional Index. J. Rheumatol., 1994; 21: 2281-2285
Google Scholar - 3. Cheng F., Wang H.W., Cuenca A. Huang M., Ghansah T., Brayer J.,Kerr W.G., Takeda K., Akira S., Schoenberger S.P., Yu H., Jove R., SotomayorE.M.: A critical role for Stat3 signaling in immune tolerance.Immunity, 2003; 19: 425-436
Google Scholar - 4. Fiocco U., Accordi B., Martini V., Oliviero F., Facco M., CabrelleA., Piva L., Molena B., Caso F., Costa L., Scanu A., Pagnin E., AttenoM., Scarpa R., Basso G., Semenzato G., Punzi L., Doria A., Dayer J.M.:JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytesreflect the in vivo T helper-17 expansion in psoriatic arthritis.Immunol. Res., 2014; 58: 61-69
Google Scholar - 5. Garrett S., Jenkinson T., Kennedy L., Whitelock H., Gaisford P.,Calin A.: A new approach to defining disease status in ankylosingspondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.J. Rheumatol., 1994; 21: 2286-2291
Google Scholar - 6. Ivashkiv L.B., Hu X.: The JAK/STAT pathway in rheumatoid arthritis:pathogenic or protective? Arthritis Rheum., 2003; 48: 2092-2096
Google Scholar - 7. Krause A., Scaletta N., Ji J.D., Ivashkiv L.B.: Rheumatoid arthritissynoviocyte survival is dependent on Stat3. J. Immunol., 2002;169: 6610-6616
Google Scholar - 8. Liang Y., Pan H.F., Ye D.Q.: Therapeutic potential of STAT4 in autoimmunity.Expert. Opin. Ther. Targets, 2014; 18: 945-960
Google Scholar - 9. Lukas C., Landewé R., Sieper J., Dougados M., Davis J., Braun J.,van der Linden S., van der Heijde D.: Development of an ASAS-endorseddisease activity score (ASDAS) in patients with ankylosingspondylitis. Ann. Rheum. Dis., 2009; 68: 18-24
Google Scholar - 10. Mease P.: Update on treatment of psoriatic arthritis. Bull. NYUHosp. Jt Dis., 2012; 70: 167-171
Google Scholar - 11. Migita K., Komori A., Torigoshi T., Maeda Y., Izumi Y., Jiuchi Y.,Miyashita T., Nakamura M., Motokawa S., Ishibashi H.: CP690,550inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoidsynoviocytes. Arthritis Res. Ther., 2011; 13: R72
Google Scholar - 12. Poddubnyy D., Brandt H., Vahldiek J., Spiller I., Song I.H., RudwaleitM., Sieper J.: The frequency of non-radiographic axial spondyloarthritisin relation to symptom duration in patients referredbecause of chronic back pain: results from the Berlin early spondyloarthritisclinic. Ann. Rheum. Dis., 2012; 71: 1998-2001
Google Scholar - 13. Reich N.C.: STATs get their move on. JAKSTAT, 2013; 2: e27080
Google Scholar - 14. Rudwaleit M., van der Heijde D., Landewé R., Akkoc N., BrandtJ., Chou C.T., Dougados M., Huang F., Gu J., Kirazli Y., Van den BoschF., Olivieri I., Roussou E., Scarpato S., Sørensen I.J., Valle-Oñate R.,Weber U., Wei J., Sieper J.: The Assessment of SpondyloArthritisInternational Society classification criteria for peripheral spondyloarthritisand for spondyloarthritis in general. Ann. Rheum. Dis.,2011; 70: 25-31
Google Scholar - 15. Rudwaleit M., van der Heijde D., Landewé R., Listing J., AkkocN., Brandt J., Braun J., Chou C.T., Collantes-Estevez E., Dougados M.,Huang F., Gu J., Khan M.A., Kirazli Y., Maksymowych W.P., MielantsH., Sørensen I.J., Ozgocmen S., Roussou E., Valle-Oñate R., Weber U.,Wei J., Sieper J.: The development of Assessment of SpondyloArthritisinternational Society classification criteria for axial spondyloarthritis(part II): validation and final selection. Ann. Rheum. Dis.,2009; 68: 777-783
Google Scholar - 16. Scott L.J.: Tofacitinib: a review of its use in adult patients withrheumatoid arthritis. Drugs, 2013; 73: 857-874
Google Scholar - 17. Smith J.A.: Update on ankylosing spondylitis: current conceptsin pathogenesis. Curr. Allergy Asthma Rep., 2015; 15: 489
Google Scholar - 18. Stark G.R., Darnell J.E.Jr.: The JAK-STAT pathway at twenty. Immunity,2012; 36: 503-514
Google Scholar - 19. Strickland I., Ghosh S.: Use of cell permeable NBD peptides forsuppression of inflammation. Ann. Rheum. Dis., 2006; 65, Suppl.3: 75-82
Google Scholar - 20. van der Heijde D., Lie E., Kvien T.K., Sieper J., Van den BoschF., Listing J., Braun J., Landewé R.: ASDAS, a highly discriminatoryASAS-endorsed disease activity score in patients with ankylosingspondylitis. Ann. Rheum. Dis., 2009; 68: 1811-1818
Google Scholar - 21. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V.,Beroukas D., Roberts-Thomson P.J., Smith M.D.: Expression of Jak3,STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3and STAT4 expression in dendritic cells in seropositive rheumatoidarthritis. Ann. Rheum. Dis., 2006; 65: 149-156
Google Scholar - 22. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V.,Beroukas D., Roberts-Thomson P.J., Smith M.D.: Changes in synovialtissue Jak-STAT expression in rheumatoid arthritis in response tosuccessful DMARD treatment. Ann. Rheum. Dis., 2006; 65: 1558-1564
Google Scholar